Pharmacokinetic and pharmacodynamic studies of supaglutide in rats and monkeys

药代动力学 药效学 加药 药理学 生物利用度 皮下注射 医学 排泄 尿 内科学 内分泌学
作者
Yijing Liao,Anran Ma,Zhihong Wang,Yue Zhou,Lin Liu,Na Zhang,Li Zhang,Gérald J. Prud’homme,Qinghua Wang
出处
期刊:European Journal of Pharmaceutical Sciences [Elsevier BV]
卷期号:175: 106218-106218 被引量:1
标识
DOI:10.1016/j.ejps.2022.106218
摘要

We demonstrated recently that supaglutide, a novel GLP-1 mimetic generated by recombinant fusion protein techniques, exerted hypoglycemic effects in type 2 diabetes db/db mice and spontaneous diabetic monkeys. In this study, we investigated the pharmacokinetics and pharmacodynamics of supaglutide by single subcutaneous and intravenous injection(s) in rats and rhesus monkeys, as well as fourconsecutive subcutaneous injections in monkeys.We found the half-life (t1/2) of supaglutide was 39.7 h and 35.8 h at dosing 0.1 mg/kg upon subcutaneous or intravenous administration respectively, in rhesus monkeys. The plasma supaglutide peaked at 8-10 h, while the plasma drug exposure levels increased with the increase of dose, showing approximately a linear pharmacokinetic characteristic. The elimination kinetics (Ke) were found to be similar between subcutaneous (∼0.025 in rats and ∼0.018 in monkeys) and intravenous administration (0.021 in rats and 0.020 in monkeys), whereas the bioavailability was found to be 31.1% in rats and 63.9% in monkeys. In monkeys, a single dose injection of supaglutide markedly decreased the random blood glucose levels that reaching the maxima effects in 14-16 h, gradually recovered and returned to the baseline level approximately after 72 h. 125I-supaglutide was found mainly distributed in the serum and organs rich in blood supply. Urine was found to be the primary excretion route of supaglutide, following by feces, but mostly not in bile.Our results show that supaglutide possess linear pharmacokinetic characteristics associated with prolonged hypoglycemic effects inanimals,suggestinga potential weekly dosing therapeutic reagent for the treatment of type 2 diabetes and metabolic diseases.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助zyq采纳,获得10
刚刚
1秒前
cctv18应助欣喜的念寒采纳,获得10
2秒前
在水一方应助科研通管家采纳,获得10
4秒前
科研通AI5应助科研通管家采纳,获得10
4秒前
科研通AI2S应助科研通管家采纳,获得10
4秒前
酷波er应助科研通管家采纳,获得10
4秒前
CipherSage应助科研通管家采纳,获得10
4秒前
合适忆南完成签到,获得积分10
5秒前
在水一方应助毅诚菌采纳,获得10
7秒前
健壮不斜完成签到 ,获得积分10
9秒前
卿莞尔完成签到 ,获得积分10
9秒前
动漫大师发布了新的文献求助20
9秒前
ycccccc完成签到 ,获得积分10
10秒前
SYLH应助霜降采纳,获得10
12秒前
午休关注了科研通微信公众号
15秒前
科研通AI2S应助平淡南松采纳,获得10
15秒前
16秒前
zzc发布了新的文献求助10
17秒前
ESLG完成签到 ,获得积分10
18秒前
二十二点36完成签到,获得积分10
20秒前
子陵完成签到 ,获得积分10
20秒前
zyq发布了新的文献求助10
21秒前
zhaoxi发布了新的文献求助10
22秒前
小天狼星发布了新的文献求助10
26秒前
27秒前
ljc发布了新的文献求助10
32秒前
姚子敏完成签到,获得积分10
32秒前
打打应助空白采纳,获得10
32秒前
兜兜揣满糖完成签到 ,获得积分10
34秒前
Halo完成签到,获得积分10
37秒前
小天狼星完成签到,获得积分10
39秒前
40秒前
mylaodao完成签到,获得积分0
40秒前
DIDI完成签到,获得积分10
40秒前
41秒前
任性晓霜完成签到,获得积分10
42秒前
所所应助平淡南松采纳,获得10
42秒前
zzc完成签到,获得积分10
43秒前
大美女完成签到,获得积分10
43秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Production Logging: Theoretical and Interpretive Elements 3000
CRC Handbook of Chemistry and Physics 104th edition 1000
Izeltabart tapatansine - AdisInsight 600
Introduction to Comparative Public Administration Administrative Systems and Reforms in Europe, Third Edition 3rd edition 500
Distinct Aggregation Behaviors and Rheological Responses of Two Terminally Functionalized Polyisoprenes with Different Quadruple Hydrogen Bonding Motifs 450
Individualized positive end-expiratory pressure in laparoscopic surgery: a randomized controlled trial 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3761774
求助须知:如何正确求助?哪些是违规求助? 3305573
关于积分的说明 10134709
捐赠科研通 3019590
什么是DOI,文献DOI怎么找? 1658226
邀请新用户注册赠送积分活动 792019
科研通“疑难数据库(出版商)”最低求助积分说明 754751